Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-2)

Clinical Trial ID NCT01708603

Rank	Title	Journal	Year	PubWeight™‹?›
1	Antibodies to watch in 2015.	MAbs	2015	1.28
2	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.	N Engl J Med	2015	1.20
3	Antibodies to watch in 2016.	MAbs	2015	1.17
4	Antibodies to watch in 2014.	MAbs	2013	1.14
5	Antibodies to watch in 2013: Mid-year update.	MAbs	2013	1.13
6	Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.	Drugs	2014	1.00
7	The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis.	Mediators Inflamm	2014	0.98
8	Psoriasis.	Cold Spring Harb Perspect Med	2014	0.85
9	The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.	Auto Immun Highlights	2014	0.83
10	Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials.	Dermatol Ther (Heidelb)	2016	0.83
11	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.	Dermatol Ther (Heidelb)	2015	0.82
12	Advances in T Helper 17 Cell Biology: Pathogenic Role and Potential Therapy in Multiple Sclerosis.	Mediators Inflamm	2015	0.79
13	Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective.	Dermatol Ther (Heidelb)	2016	0.75
14	Abstracts.	J Invest Dermatol	2015	0.75